A comparison of risperidone-induced weight gain across the age span

Journal of Clinical Psychopharmacology

Volumn 24, Issue 4, 2004, Pages 429-436

  Safer, Daniel J ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG SENSITIVITY; HUMAN; META ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; CHILD; CHILD, PRESCHOOL; HUMANS; RISPERIDONE; WEIGHT GAIN;

EID: 3242658146     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000130558.86125.5b     Document Type: Review

References (88)

1. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;62:92-100.
2. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizo-affective disorder. Am J Psychiatry. 2001;158:765-774.
3. Jones B, Bassson BR, Walker DJ, et al. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry. 2001;62(suppl 2):41-44.
4. Sussman N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol. 2003;23(suppl 1):S21-S26.
5. Biederman J, Faraone SV, Spenser TJ. Extended-release mixed amphetamine salts in ADHD: group parameter analysis. Paper presented at: 156th Annual Meeting of the American Psychiatric Association; May 19, 2003; San Francisco, CA.
6. Safer DJ, Allen RP. Factors influencing the suppressant effects of two stimulant drugs on the growth of hyperactive children. Pediatrics. 1973;51:660-667.
7. Sund AM, Zeiner P. Does extended medication with amphetamine or methlyphenidate reduce growth in hyperactive children? Nord J Psychiatry. 2002;56:53-57.
8. Wetterling T, Murigbrodt HE. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol. 1999;19:316-321.
9. Lane HY, Chang YC, Cheng YC, et al. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J Clin Psychiatry. 2003;64:316-320.
10. Needlman RD. Growth and development. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson Textbook of Pediatrics. 16th ed. Philadelphia: Saunders. 2000:44-46.
11. Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Dev Disord. 1997;27:313-323.
12. Malone RP, Maislin G, Choudhury MS, et al. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psych. 2002;41:140-147.
13. Van Bellinghen M, Troch CD. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo controlled pilot trial. J Child Adolesc Psychopharmacol. 2001;11:5-13.
14. Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled trial of risperidone in Tourette Syndrome. Paper presented at: Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October, 2001; Honolulu, HI.
15. Armenteros JL, Whitaker AH, Welikson M, et al. Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psych. 1997;36:694-700.
16. Buitelaar JK, Gaag RJ, Kettenis PC, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001;62:239-248.
17. Synder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psych. 2002;41:1026-1036.
18. Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159:1337-1346.
19. Perry R, Pataki C, Silva DM, et al. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc Psychopharmacol. 1997;7:167-179.
20. Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull. 1997;33:155-159.
21. Martin A, Landau J, Leebens P, et al. Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol. 2000;10:259-268.
22. Sikich L, Horrigan JP, Lieberman JA, et al. Comparative use of olanzapine and risperidone in psychotic youth. Paper presented at: Annual Meeting of the American Psychiatric Association; May 2001; New Orleans, LA.
23. Gaffney GR, Perry PJ, Lund BC, et al. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psych. 2002;41:330-336.
24. Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60:1130-1135.
25. The RUPP Autism Network, McCracken JT. Risperidone in children with autism and serious behavioral problems. NEJM. 2002;347:314-321.
26. Findling RL, McNamara NK, Branicky LA, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psych. 2000;39:509-516.
27. Lombroso PJ, Scahill L, King RA, et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psych. 1995;34:1147-1152.
28. Nicolson R, Awad G, Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psych. 1998;37:372-376.
29. McDougle CJ, Holmes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psych. 1997;36:685-693.
30. Sikich L. Controlled trials of antipsychotics in psychotic youth. Paper presented at: Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 2001; Honolulu, HI.
31. Correll CU, Parikh UH, Kane JM, et al. Novel antipsychotic-induced weight gain and metabolic effects in children and adolescents with psychotic and aggressive disorders. Paper presented at: Annual Meeting of the Clinical Research Conference; March 2003; Baltimore, MD.
32. Findling R, Aman MG, Smedt G, et al. Long-term safety and efficacy of risperidone in children with significant conduct problems and borderline IQ or mental retardation. Paper presented at: New Clinical Drug Evaluation Unit Annual Meeting; May 2001; Phoenix, AZ.
33. Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psych. 2002;41:337-343.
34. Grcevich S, Melamed L, Richards R, et al. Comparative side effects of atypical neuroleptics in children and adolescents. Paper presented at: Annual Meeting of the American Psychiatric Association; May 2000; Chicago, IL.
35. Masi G, Consenza A, Mucci M, et al. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psych. 2001;40:1206-1214.
36. Hellings JA, Zarcone JR, Crandall K, et al. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol. 2001;11:229-238.
37. Aman MG. Effects of antipsychotics on the behavior of children with sub-average IQs and severe conduct problems. Paper presented at: Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 2001; Honolulu, HI.
38. Casena M, Gonzolez-Heydrich J, Szigethy E, et al. A case series of eight aggressive young children treated with risperidone. J Child Adolesc Psychopharmacol. 2002;12:327-345.
39. L'Ecuyer SN. Triglyceride, cholesterol, and weight changes among risperidone-treated youths. Paper presented at: Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 2001; Honolulu, HI.
40. Zuddas A, Martino AD, Muglia P, et al. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability and discontinuation. J Child Adolesc Psychopharmacol. 2000;10:79-90.
41. Kelly DL, Conley RR, Love RC, et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol. 1998;8:151-159.
42. Turgay A, Binder C, Snyder R, et al. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics. 2002;110(3):e34.
43. Szigethy E, Wiznitzer M, Branicky LA, et al. Risperidone-induced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol. 1999;9:93-98.
44. Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry. 2001;62:231-238.
45. Simpson MM, Goetz RR, Devlin MJ, et al. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods. J Clin Psychiatry. 2001;62:694-700.
46. Labelle A, Light M, Dunbar F. Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response. Can J Psychiatry. 2001;46:534-541.
47. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry. 1995;166:712-726.
48. Bondolfi G, Dufour H, Parris M. Risperidone versus clozepine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry. 1998;155:499-504.
49. Addington D, Benattia I, Pantelis C, et al. Ziprasidone vs risperidone in schizophrenia: efficacy and safety in an 8-week trial. Poster presented at: New Clinical Drug Evaluation Units Annual Meeting; June 2002; Boca Raton, FL.
50. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
51. Claus A, Bollen J, DeCuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand. 1992;85:295-305.
52. Czobor P, Volavka J, Sheitman B, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol. 2002;22:244-251.
53. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997;17:407-418.
54. Csernansky J, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16-22.
55. Meyer JM. A retrospective comparison of weight, lipid and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic changes after 1 year. J Clin Psychiatry. 2003;61:428-433.
56. Russell JM, Mackell JA, Martinez JM. Average dose and weight: olanzapine vs. risperidone. Paper presented at: New Clinical Drug Evaluation Unit Annual Meeting; June 1999; Boca Raton, FL.
57. Cohen S, Glazewski R, Khan S, et al. Weight gain with risperidone among patients with mental retardation: effect of caloric restriction. J Clin Psychiatry. 2001;62:114-116.
58. Madhusoodanan S, Suresh P, Brenner R, et al. Experience with the atypical antipsychotics-risperidone and olanzapine in the elderly. Ann Clin Psychiatry. 1999;11:113-118.
59. Rainer MK, Masching AJ, Ertl MG, et al. Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia. J Clin Psychiatry. 2001;62:894-900.
60. De Deyn PP, Rabheru K, Rassmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946-955.
61. Brodaty H, Ames D, Snowdon J, et al. A random placebo-controlled trial of risperidone for the treatment of aggression, agitation and psychosis of dementia. J Clin Psychiatry. 2003;64:134-143.
62. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry. 1999;60:107-115.
63. Frenchman LB, Capo A, Pieniro MY, et al. Behavior, side effect and drug failure comparison study of risperidone, haloperidol, olanzapine and quetiapine. Paper presented at: Annual Meeting of the American Psychiatric Association; May 1999; Washington DC.
64. Barak Y, Shamir E, Weizman R. Would a switch from a typical antipsychotic to risperidone be beneficial for elderly schizophrenic patients? J Clin Psychopharmacol. 2002;22:115-120.
65. Barak Y. No weight gain among elderly schizophrenic patients after 1 year of risperidone treatment. J Clin Psychiatry. 2002;63:117-119.
66. Bruggeman R, Linden C, Buitelaar JK, et al. Risperidone versus pimozide in Tourettes's disorder: a comparative double-blind parallel-group study. J Clin Psychiatry. 2001;162:50-56.
67. Zarcone JR, Hellings JA, Crandall K, et al. Effects of risperidone on aberrant behavior of persons with developmental disabilities. Am J Ment Retard. 2001;106:525-538.
68. Blackburn GL. Weight gain and antipsychotic medication. J Clin Psychiatry. 2000;61(suppl 8):36-41.
69. Conley RR. Risperidone side effects. J Clin Psychiatry. 2000;61(suppl 8): 20-23.
70. Guille C, Sachs GS, Ghaemi SN. A nationalistic comparison of clozapine, risperidone and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2000;61:638-642.
71. Ogden CL, Kuczmarski RJ, Flegal KM, et al. Centers for disease control and prevention 2000 growth charts for the United States. Pediatrics. 2002;109:45-60.
72. Masand PS. Side effects of antipsychotics in the elderly. J Clin Psychiatry. 2000;61(suppl 8):43-51.
73. Street JS, Clark WS, Kadam DL, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Int J Geriatr Psychiatry. 2001;16:S62-S70.
74. Woods SW, Martin A, Spector SG, et al. Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psych. 2002;41:1439-1446.
75. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry. 1997;58(suppl 10):45-49.
76. Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania. Am J Psychiatry. 2002;159:1146-1154.
77. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59:62-69.
78. Sonnenberg JG, Reinstein MJ, Mohan SC, et al. A non-tapered switch from quetiapine to olanzapine in psychotic older adults. J Clin Psychiatry. 2002;63:1081.
79. Weber E, Stack J, Pollack BG, et al. Weight change in older depressed patients during acute pharmacotherapy with paroxetine and nortryptyline. Am J Geriatr Psychiatry. 2000;8:245-250.
80. Kando J, Tohen M, Castillo J, et al. The use of valproate in an elderly population with affective symptoms. J Clin Psychiatry. 1996;57:238-240.
81. Kennedy JS, Bymaster FP, Schuh L, et al. A current review of olanzapine's safety in the geriatric patient. Int J Geriatr Psychiatry. 2001;16:S33-S61.
82. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561-566.
83. Etminan M, Steiner DL, Rochon PA. Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy. 2003;23:1411-1415.
84. Reilly JJ, Brougham M, Montgomery C, et al. Effect of glucocorticoid therapy on energy intake in children treated for acute lymphoblastic leukemia. J Clin Endocrinol Metab. 2001;86:3742-3745.
85. Biton V, Levisohn P, Hoyler S, et al. Lamotrogine versus valproate monotherapy-associated weight change in adolescents with epilepsy. J Child Neurol. 2003;18:133-139.
86. Dunger D, Ahmed L, Ong K. Growth and body composition in type 1 diabetes mellitus. Horm Res. 2002;58(suppl 1):66-71.
87. Vitiello B, Jensen PS. Developmental perspectives in pediatric psycho-pharmacology. Psychopharmacol Bull. 1995;31:75-81.
88. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62(suppl 7):22-31.